<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/c:/OANC/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="2233" end="2237" sStart="-1" offset="0" sid="null" wn="1" wnkey="work%1:04:00::" annotator="carichter" text="The official responsible for GAO evaluation &lt;b&gt;work&lt;/b&gt; relating to the Department of Health and Human Services, Food and Drug Administration, is William Scanlon, Director, Health Financing and Public Health Issues." />
    <s path="[OANC]/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="4902" end="4907" sStart="null" offset="26" sid="r7.1.use.v.0423" wn="1" wnkey="use%2:34:01::" annotator="brubin" text="The final rule was issued using the notice and comment procedures found at 5 U.S.C." />
    <s path="[OANC]/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="557" end="563" sStart="null" offset="52" sid="r8.state.n.0675" wn="2147483647" wnkey="null" annotator="brubin" text="Pursuant to section 801(a)(2)(A) of title 5, United States Code, this is our report on a major rule promulgated by the Department of Health and Human Services, Food and Drug Administration (FDA), entitled &quot;Over-the-Counter Human Drugs; Labeling Requirements&quot; (RIN: 0910-AA79)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="1381" end="1384" sStart="null" offset="0" sid="null" wn="4" wnkey="meet%2:34:00::" annotator="brubin" text="The FDA gives no reason in the rule's preamble as to why the 60-day delay provision was not &lt;b&gt;met&lt;/b&gt;." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="701" end="709" sStart="null" offset="0" sid="null" wn="2" wnkey="entitle%2:32:00::" annotator="veweser" text="Pursuant to section 801(a)(2)(A) of title 5, United States Code, this is our report on a major rule promulgated by the Department of Health and Human Services, Food and Drug Administration (FDA), &lt;b&gt;entitled&lt;/b&gt; &quot;Over-the-Counter Human Drugs; Labeling Requirements&quot; (RIN: 0910-AA79)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="701" end="709" sStart="null" offset="0" sid="null" wn="2" wnkey="entitle%2:32:00::" annotator="cgozo" text="Pursuant to section 801(a)(2)(A) of title 5, United States Code, this is our report on a major rule promulgated by the Department of Health and Human Services, Food and Drug Administration (FDA), &lt;b&gt;entitled&lt;/b&gt; &quot;Over-the-Counter Human Drugs; Labeling Requirements&quot; (RIN: 0910-AA79)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="701" end="709" sStart="null" offset="0" sid="null" wn="2" wnkey="entitle%2:32:00::" annotator="cgozo" text="Pursuant to section 801(a)(2)(A) of title 5, United States Code, this is our report on a major rule promulgated by the Department of Health and Human Services, Food and Drug Administration (FDA), &lt;b&gt;entitled&lt;/b&gt; &quot;Over-the-Counter Human Drugs; Labeling Requirements&quot; (RIN: 0910-AA79)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="701" end="709" sStart="null" offset="0" sid="null" wn="2" wnkey="entitle%2:32:00::" annotator="brubin" text="Pursuant to section 801(a)(2)(A) of title 5, United States Code, this is our report on a major rule promulgated by the Department of Health and Human Services, Food and Drug Administration (FDA), &lt;b&gt;entitled&lt;/b&gt; &quot;Over-the-Counter Human Drugs; Labeling Requirements&quot; (RIN: 0910-AA79)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="701" end="709" sStart="null" offset="0" sid="null" wn="2" wnkey="entitle%2:32:00::" annotator="brubin" text="Pursuant to section 801(a)(2)(A) of title 5, United States Code, this is our report on a major rule promulgated by the Department of Health and Human Services, Food and Drug Administration (FDA), &lt;b&gt;entitled&lt;/b&gt; &quot;Over-the-Counter Human Drugs; Labeling Requirements&quot; (RIN: 0910-AA79)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="1479" end="1483" sStart="null" offset="0" sid="null" wn="6" wnkey="date%1:28:05::" annotator="brubin" text="While the rule has varying compliance &lt;b&gt;dates&lt;/b&gt; that are much later than the announced effective &lt;b&gt;date&lt;/b&gt; of the rule (some previously approved products covered by the rule have several years to become compliant with the labeling requirement), we do note" />
    <s path="[OANC]/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="3134" end="3142" sStart="null" offset="77" sid="r11.benefit.n.0141" wn="2" wnkey="benefit%1:07:00::" annotator="adelpriore" text="The health benefits could not be quantified by the FDA, but FDA believes the benefits to be substantial." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="1573" end="1579" sStart="null" offset="0" sid="null" wn="2" wnkey="become%2:42:01::" annotator="veweser" text="While the rule has varying compliance dates that are much later than the announced effective date of the rule (some previously approved products covered by the rule have several years to &lt;b&gt;become&lt;/b&gt; compliant with the labeling requirement), we do note" />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/government/Gen_Account_Office/og99036.anc" start="1573" end="1579" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" annotator="tofox" text="While the rule has varying compliance dates that are much later than the announced effective date of the rule (some previously approved products covered by the rule have several years to &lt;b&gt;become&lt;/b&gt; compliant with the labeling requirement), we do note" />
  </sentences>
</list>